Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
AMAmarin Corporation plc logo

Amarin Corporation plc (AMRN)

NASDAQ Global Market · Currency in USD
$11.79 ▲ +0.19 (+1.64%)
At close: Oct 23, 4:00 PM ET. Market closed.
$11.41 ▼ -0.38 (-3.24%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$11.60
Open
$11.62
Day's Range
$11.50 – $11.93
52 Week Range
$11.25 – $20.57
Volume
82,768
Avg. Volume
71,019
Market Cap
$243.85M
Beta (5Y Monthly)
0.77
PE Ratio (TTM)
--
EPS (TTM)
-$1.30
Earnings Date
Oct 28, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$2.17

Profile: Amarin Corporation plc

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
80
CEO
Aaron D. Berg

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only.

Earnings

Next report: Wed, Oct 28, 2026
EPS estimate -$0.10 · Revenue est. $43.76M
DateEst.Actual
Jul 29, 2026-$0.01-$0.02Miss
Apr 29, 2026$0.01-$0.09Miss
Feb 25, 2026$0.07$0.01Miss
Oct 29, 2025$0.08$0.01Miss
Jul 30, 2025-$0.66-$0.03Beat
May 7, 2025-$1.12-$0.04Beat

Analyst view

Consensus price target
$2.17 ▼ -81.6%
Range $1.50 – $3.00
Rating: Hold
Buy 17% · Hold 72% · Sell 11%

Get free alerts on AMRN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.